Last reviewed · How we verify

NCT04248283

Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

Recruiting now NA Last updated 23 July 2024
What this trial tests

NA trial testing Adjustable Continence Therapy for Women (ACT) in Urinary Incontinence in 167 participants. Currently enrolling.

Timeline
26 January 2021
Primary endpoint
30 September 2025
30 December 2025

Quick facts

Lead sponsorUromedica
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment167
Start date26 January 2021
Primary completion30 September 2025
Estimated completion30 December 2025
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Uromedica

Who can join

22 and older, female only, with Urinary Incontinence or Urinary Incontinence,Stress. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Urinary Incontinence

Currently open trials in the same condition.

Other Uromedica trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04248283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing